false
0001818382
0001818382
2025-11-21
2025-11-21
0001818382
us-gaap:CommonStockMember
2025-11-21
2025-11-21
0001818382
HUMA:RedeemableWarrantsEachWholeWarrantExercisableForOneOfCommonAtExercisePriceOf11.50Member
2025-11-21
2025-11-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported):
November 21, 2025
Humacyte, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-39532 |
|
85-1763759 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification Number) |
|
2525 East North Carolina Highway 54
Durham, NC |
|
27713 |
| (Address of principal executive offices) |
|
(Zip code) |
(919) 313-9633
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
| Common
Stock, par value $0.0001 per share |
|
HUMA |
|
The Nasdaq Stock Market LLC |
| Redeemable
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 |
|
HUMAW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
Item 1.02. Termination of a Material Definitive Agreement
As previously disclosed, on
September 1, 2022, Humacyte, Inc. (the “Company”) entered into an Open Market Sale Agreement™ (the “Agreement”)
with Jefferies LLC (“Jefferies”), under which the Company may offer and sell its common stock, par value $0.0001 per share,
from time to time having an aggregate offering price of up to $80,000,000 during the term of the Agreement through Jefferies, acting as
agent.
On November 21, 2025, the Company delivered a notice to Jefferies terminating
the Agreement, which termination will become effective under the Agreement 10 days thereafter. The Company is not subject to any termination
penalties related to the termination of the Agreement. A copy of the Agreement was filed as Exhibit 1.2 to the Company’s Registration
Statement on Form S-3 (File No. 333-267225) filed with the Securities and Exchange Commission on September 1, 2022.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
HUMACYTE, INC. |
| |
|
|
| Date: November 26, 2025 |
By: |
/s/ Dale A. Sander |
| |
|
Name: |
Dale A. Sander |
| |
|
Title: |
Chief Financial Officer, Chief Corporate Development Officer and Treasurer |
